期刊
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
卷 7, 期 2, 页码 85-96出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1758834014567470
关键词
immune checkpoint modulator; nivolumab; non-small cell lung cancer; programmed death-1; programmed death-1 ligand
类别
资金
- National Research Foundation, Singapore
- Singapore Ministry of Education
New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player in evading host immune response. The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. This review will discuss results from early phase studies of nivolumab in solid tumors including non-small cell lung cancer (NSCLC) as well as studies of nivolumab in combination with chemotherapy, other immune modulators and molecular targeted therapy in patients with NSCLC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据